VERA News and Press, Vera Therapeutics Inc. From 07/14/21

SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment...

Vera Therapeutics (VERA): Q1 GAAP EPS of -$12.23.Vera reported approximately $49.5 million in cash and cash equivalents as of March 31, 2021.Press Release For further details see: Vera Therapeutics reports Q1 results

Completed an initial public offering with net proceeds, including the exercise of the underwriters’ option in full, of approximately $48.4 million in May 2021 - - - Expanded the management team to support initiation of atacicept clinical development program ...

Point Roberts, WA and Delta, BC - June 18, 2021 (Investorideas.com Newswire) Investorideas.com , a global news source and leading retail investor and trader resource, announces its weekly roundup of stocks to watch in Biotech and Mining. Today's stocks have been added to our lists of fr...

Evercore ISI analyst Liisa Bayko initiates coverage on Vera Therapeutics ([[VERA]] +15.5%) with an Outperform rating, and price target ((PT)) set to $24.Vera was also rated new buy at Jefferies, analyst Maury Raycroft set PT to $27.In addition, Vera was initiated with an Outperform rating at ...

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that management ...

Recently IPO’ed clinical-stage biotech company Vera Therapeutics ([[VERA]] -10.3%) is trading lower today for the third consecutive day.Having lost more than a tenth value so far, the company appears to be on track to record its biggest one-day loss since its public debut on May 14.How...

Vera Therapeutics (VERA) soared more than 75% intraday as the biotech’s stock extended a post-IPO rally into five sessions.VERA rose to as high as $26.97, up 75.7% for the day and 145.2% from the $11 a share that the stock’s initial public offering priced at just last week. The ...